How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

51 results for

Midparental Height

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Midparental Height

Midparental Height Midparental Height Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Midparental Height Midparental Height Aka (...) : Midparental Height , Calculation of Growth Delay , Calculation of Growth Excess II. Approach: Step 1 - Calculate Final Height prediction (mid-parental height) Boy In: (Father's Height + Mother's Height + 5) / 2 Cm: (Father's Height + Mother's Height + 13) / 2 Girl In: (Father's Height - 5 + Mother's Height) / 2 Cm: (Father's Height - 13 + Mother's Height) / 2 III. Approach: Step 2 - Identify Predicted Growth Percentile Use above predicted mean height to mark growth chart Mark chart at 18-20 year old mark

2018 FP Notebook

2. Midparental Height

Midparental Height Midparental Height Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Midparental Height Midparental Height Aka (...) : Midparental Height , Calculation of Growth Delay , Calculation of Growth Excess II. Approach: Step 1 - Calculate Final Height prediction (mid-parental height) Boy In: (Father's Height + Mother's Height + 5) / 2 Cm: (Father's Height + Mother's Height + 13) / 2 Girl In: (Father's Height - 5 + Mother's Height) / 2 Cm: (Father's Height - 13 + Mother's Height) / 2 III. Approach: Step 2 - Identify Predicted Growth Percentile Use above predicted mean height to mark growth chart Mark chart at 18-20 year old mark

2015 FP Notebook

3. Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level (PubMed)

was significantly shorter than the midparental height (MPH), whereas PAH at end of therapy approached MPH, and NFH was greater than MPH. Height velocity (HV) in the overweight group was higher during GnRHa therapy than that in the normal-weight group, but those in the two groups were not different after therapy until NFH. Both BMISDS-CA and BMISDS-BA increased significantly during therapy, but both BMISDSs decreased significantly after therapy until NFH. At NFH, neither BMISDS was different from (...) Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and after gonadotropin-releasing hormone analog (GnRHa) treatment are inconsistent. We, therefore, investigated auxological parameters in GnRHa-treated girls with idiopathic CPP (ICPP) until

Full Text available with Trip Pro

2018 Annals of pediatric endocrinology & metabolism

4. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. (PubMed)

with pretreatment predicted AH, AH significantly exceeded predicted AH at treatment onset (173.8 ± 6.9 vs 164.9 ± 10.7 cm; P < .001), but fell short of predicted AH at treatment discontinuation (177.3 ± 9.0 cm; P < .001). For 11 subjects with maternal or sporadic inheritance, the mean AH was 3.1 cm (0.4 SD score) below sex-adjusted midparental height (175.4 ± 5.8 vs 178.5 ± 3.1 cm [midparental height]; P = .10). For 16 subjects with affected and untreated fathers, AH was significantly greater than fathers' AH (...) (172.8 ± 7.4 vs 168.8 ± 7.2 cm; P < .05).Long-term treatment with antiandrogen, aromatase inhibitor, and GnRHa in boys with FMPP results in AH modestly below sex-adjusted midparental height and within the range for adult males in the general population.Published by Elsevier Inc.

Full Text available with Trip Pro

2017 Journal of Pediatrics

5. Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. (PubMed)

; the reference sections of included studies; and expert files.Eligible studies included patients diagnosed with CAH before age 5 and followed to final height.Reviewers working in duplicate independently extracted data on study characteristics and outcomes and determined each study's risk of bias.The sd score (SDS) for final height and corrected height (defined as final height SDS - midparental height SDS) were estimated from each study and pooled using random-effects metaanalysis. The I(2) statistic was used (...) Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. Treatment for patients with congenital adrenal hyperplasia (CAH) may affect the final height of these patients.Our objective was to determine the distribution of achieved height in patients with classic CAH diagnosed at infancy or early childhood and treated with glucocorticoids.We searched MEDLINE, EMBASE, Cochrane Library, ISI Web of Science, and Scopus through September 2008

Full Text available with Trip Pro

2010 The Journal of clinical endocrinology and metabolism

6. Hypothalamic - Pituitary and Growth Disorders in Survivors of Childhood Cancer

midparental height. Studies of GHD childhood cancer survivors treated with GH who were exposed to spinal irradiation also suggest a reduced benefit of GHT after spinal irradiation. Ciaccio et al. ( ) found that among GH-deficient medulloblastoma survivors treated with 26 to 38 Gy CSI, the mean adult standing height decreased from −1.38 SD to −1.9 SD at AH in those treated with GH, whereas the standing height of those not treated with GH decreased from −1.55 SD to −3.4 SD. However, spinal heights in both (...) /impaired linear growth in childhood cancer survivors 1.1 We recommend prospective follow-up of linear growth for childhood cancer survivors at high risk for short adult height, namely those exposed to cranial radiation therapy, craniospinal irradiation, or total body irradiation at a young age and those with a history of inadequate weight gain or prolonged steroid requirement. (1∣⊕⊕⊕O) 1.2 We recommend measuring standing height and sitting height in childhood cancer survivors treated with radiation

Full Text available with Trip Pro

2018 The Endocrine Society

8. Efficacy of Growth Hormone Treatment in Children with Type 1 Diabetes Mellitus and Growth Hormone Deficiency-An Analysis of KIGS Data. (PubMed)

developed T1DM before GHD and were included in this analysis. Of 30 570 patients with GHD without T1DM, 15 024 were prepubertal and served as controls. Values are expressed as mean ± SD.Patients with T1DM and GHD had similar characteristics compared with the GHD-alone group. Neither age (10.2 ± 3.13 vs 8.42 ± 3.46 years, P = .14), height SDS corrected for midparental height SDS at start of treatment (-1.62 ± 1.38 vs -1.61 ± 1.51, P = .80), nor GH dosage (0.24 ± 0.08 mg/kg/wk vs 0.20 ± 0.04 mg/kg/wk, P (...)  = .09) were different between those with and without T1DM. First-year catch-up growth was comparable between the 2 patient groups (first treatment year height velocity 7.54 ± 3.11 cm/year compared with 8.35 ± 2.54 cm/year in control patients, P = .38). Height SDS of children with T1DM and GHD improved from -2.62 ± 1.04 to -1.88 ± 1.11 over 1 year of GH treatment.Short-term response to GH therapy appeared similar in subjects with T1DM who then developed GHD and in those with GHD alone. Thus, T1DM

2018 Journal of Pediatrics

9. 45,X/46,XY mosaicism presenting with isolated unilateral cryptorchidism and a normal blood karyotype. (PubMed)

descended testis was present. The karyotype of the removed gonad was 45,X/46,XY. The child grew along the second centile, within the midparental height (MPH) range, until the time of puberty, when linear growth worsened due to a lack of a pubertal growth spurt, and growth hormone (GH) therapy was initiated. He developed spontaneous puberty (13 years of age) and showed normal pubertal progression. However, from the age of 15 years, he had low normal testosterone, raised follicle-stimulating hormone (...) , and reduction of inhibin B, possibly suggestive of declining testicular function. His final height was -2.24 standard deviation score (SDS) (-2.4 SDS at GH start; MPH -1.6 SDS).Our case describes a mild male phenotype associated with 45,X/46,XY mosaicism characterized by unilateral cryptorchidism, spontaneous onset of puberty, and normal blood karyotype. The case illustrates the difficulties inherent in making a diagnosis of 45,X/46,XY mosaicism when there is no genital ambiguity and makes the point

Full Text available with Trip Pro

2018 Journal of Clinical Endocrinology and Metabolism

10. Impact of dietary nutrient intake and physical activity on body composition and growth in Indian children. (PubMed)

recorded.ResultsMean daily energy and protein intakes as recommended dietary allowance were significantly lower in both boys and girls (P<0.01) above 6 years, with 55% reduction in micronutrient intakes in older children. When compared with World Health Organization references, lower heights in pubertal boys and girls were related to dietary energy and protein intake. Multiple regression analysis showed positive association of height for age z-scores (HAZ) with midparental height z-scores (β=0.45, P=0.0001 (...) Impact of dietary nutrient intake and physical activity on body composition and growth in Indian children. BackgroundTo investigate interrelationships of dietary composition and physical activity (PA) with growth and body composition (BC) in urban Indian school children.MethodsA cross-sectional study was performed in 4,747 Indian school children (2,623 boys) aged 3-18 years. Weight, height, BC by body impedance analyzer, PA and dietary food intakes by questionnaire method were

2017 Pediatric Research

11. Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty (PubMed)

), difference between BA and CA (BA-CA), standard deviation score (SDS) of height, body mass index (BMI), predicted adult height (PAH), and laboratory findings were compared at baseline, after 1 year, and at the end of GnRHa treatment in both groups.Mean BMI SDS at baseline was 0.08±0.60 in the normal weight group and 1.55±0.36 in the overweight/obesity group. Initial CA, BA, midparental height, and PAH were similar between the 2 groups. BA-CA after treatment was significantly decreased compared to baseline (...) treatment in obese girls with CPP improved the height outcome and had similar results in normal weight CPP girls. Obesity might not affect the efficacy of GnRHa in girls with CPP.

Full Text available with Trip Pro

2017 Annals of pediatric endocrinology & metabolism

12. Growth without growth hormone in combined pituitary hormone deficiency caused by pituitary stalk interruption syndrome (PubMed)

diagnosed a female patient aged 13 with combined pituitary hormone deficiency (CPHD) caused by pituitary stalk interruption syndrome (PSIS). The patient has experienced recurrent hypoglycemic seizures since birth, but reached the height of 160 cm at the age of 13, showing normal growth. She grew another 8 cm for 3 years after the diagnosis, and she reached her final adult height of 168 cm which was greater than the midparental height, at the age of 16. The patient's blood GH and insulin-like growth (...) factor-I levels were consistently subnormal, although her insulin levels were normal. Her physical examination conducted at the age of 15 showed truncal obesity, dyslipidemia, and osteoporosis, which are metabolic features of GH deficiency (GHD). Herein, we report a case in which a PSIS-induced CPHD patient attained her final height above mid parental height despite a severe GHD.

Full Text available with Trip Pro

2017 Annals of pediatric endocrinology & metabolism

13. Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency (PubMed)

and biochemical changes including chronologic age (CA), bone age (BA), height standard deviation score (HT-SDS), predicted adult height (PAH), midparental height (MPH), insulin-like growth factor-1 (IGF-1), and insulin-like growth factor binding protein-3 (IGFBP-3) were compared.Before treatment, IGHD group had younger BA, lower BA/CA ratio, and lower IGF-1 level than those in the ISS group. During GH treatment, the levels of IGF-1 and IGFBP-3 were not different. Although annual BA increment was higher

Full Text available with Trip Pro

2017 Annals of pediatric endocrinology & metabolism

14. Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

: Participated in the 'GH-dose catch-up study' 98- 0198-003. Midparental height reached (difference less than 0.6 SDS) Prepubertal at start of the study (girls =B 1, boys: testes :<; 3ml). Signed written informed consent from the patient's parents (and the child if old enough) Exclusion Criteria: Disease affecting growth other than correctly treated hypothyroidism. Incapable of following the study protocol (i.e. bad compliance in the previous study). Puberty (> breast stage 2, or testes > 4ml). Poor (...) Posted : August 26, 2016 Last Update Posted : January 2, 2018 Sponsor: Göteborg University Collaborator: Pfizer Information provided by (Responsible Party): Göteborg University Study Details Study Description Go to Brief Summary: The objective was to study whether normal growth velocity can be maintained with adapted GH dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled catch up growth (=difference to target height reached, less than - 0.6 SDS). Condition

2016 Clinical Trials

16. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children. (PubMed)

, height gain, or difference in height to midparental heightSDS between genotype groups were found at adult height.The common GHR d3/fl polymorphism is probably not a cause of DICT in children with ISS, and our results do not suggest that the d3-GHR genotype is associated with increased sensitivity to GH in children with ISS.Copyright © 2015 Elsevier Ltd. All rights reserved. (...) short stature (ISS).Study subjects included 167 prepubescent longitudinally followed children classified as having ISS. Children were randomized to standard-dose GH treatment (33 μg kg(-1) day(-1)), to double-dose treatment (67 μg kg(-1) day(-1)), or to an untreated control group. Growth and metabolic outcome were evaluated at birth (n = 166), after one year of treatment (n = 59) and at adult height (n = 145). Genotyping of the GHR d3/fl polymorphism was performed using TaqMan SNP genotyping

2015 Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

17. Growth Hormone Dose-Dependent Pubertal Growth: A Randomized Trial in Short Children with Low Growth Hormone Secretion. (PubMed)

Growth Hormone Dose-Dependent Pubertal Growth: A Randomized Trial in Short Children with Low Growth Hormone Secretion. Growth hormone (GH) treatment regimens do not account for the pubertal increase in endogenous GH secretion. This study assessed whether increasing the GH dose and/or frequency of administration improves pubertal height gain and adult height (AH) in children with low GH secretion during stimulation tests, i.e. idiopathic isolated GH deficiency.A multicenter, randomized, clinical (...) trial (No. 88-177) followed 111 children (96 boys) at study start from onset of puberty to AH who had received GH 33 µg/kg/day for ≥1 year. They were randomized to receive 67 µg/kg/day (GH(67)) given as one (GH(67×1); n = 35) or two daily injections (GH(33×2); n = 36), or to remain on a single 33 µg/kg/day dose (GH(33×1); n = 40). Growth was assessed as heightSDSgain for prepubertal, pubertal and total periods, as well as AHSDS versus the population and the midparental height.Pubertal heightSDSgain

2014 Hormone research in paediatrics

19. Osteoporosis in Solid Organ Transplantation (Treatment)

transplant during these critical years would fail to accrue normal bone mass or delay achievement of peak bone mass. A cross-sectional case control study of 9 patients who were 12-16 years old at the time of cardiac transplantation found that at 8-16 years posttransplant, transplant recipients had shorter stature than calculated midparental height would predict. [ ] Biochemical parameters suggested renal impairment with secondary hyperparathyroidism, without a difference in vitamin D levels between (...) of amenorrhea and hypogonadism are also at increased risk Previous Next: Clinical Presentation Patient history The pretransplant bone evaluation should include a careful history with particular attention to risk factors for osteoporosis. Any personal history of fracture is particularly relevant because prior fracture predicts future fracture. [ ] Any family history of osteoporosis or fragility fractures is also relevant. A history of loss of height suggests established osteoporosis and occult thoracic

2014 eMedicine.com

20. Osteoporosis in Solid Organ Transplantation (Overview)

transplant during these critical years would fail to accrue normal bone mass or delay achievement of peak bone mass. A cross-sectional case control study of 9 patients who were 12-16 years old at the time of cardiac transplantation found that at 8-16 years posttransplant, transplant recipients had shorter stature than calculated midparental height would predict. [ ] Biochemical parameters suggested renal impairment with secondary hyperparathyroidism, without a difference in vitamin D levels between (...) of amenorrhea and hypogonadism are also at increased risk Previous Next: Clinical Presentation Patient history The pretransplant bone evaluation should include a careful history with particular attention to risk factors for osteoporosis. Any personal history of fracture is particularly relevant because prior fracture predicts future fracture. [ ] Any family history of osteoporosis or fragility fractures is also relevant. A history of loss of height suggests established osteoporosis and occult thoracic

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>